{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:28:51Z","timestamp":1793964531867,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["ZHOU KE HE YI XUE 2025-1"],"award-info":[{"award-number":["ZHOU KE HE YI XUE 2025-1"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260106"],"award-info":[{"award-number":["82260106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinsp.2026.100865","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:26:08Z","timestamp":1770038768000},"page":"100865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4352-0658","authenticated-orcid":false,"given":"Zhixun","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4139-4815","authenticated-orcid":false,"given":"Jiaxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5565-0048","authenticated-orcid":false,"given":"Yongping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3127-0713","authenticated-orcid":false,"given":"Houze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7388-4030","authenticated-orcid":false,"given":"Rubin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2313-8196","authenticated-orcid":false,"given":"Miao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1795-288X","authenticated-orcid":false,"given":"Wenyi","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clinsp.2026.100865_bib0001","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"10.1016\/j.clinsp.2026.100865_bib0002","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clinsp.2026.100865_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102747","article-title":"Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1\/2 trial","volume":"74","author":"Gurumurthi","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.clinsp.2026.100865_bib0004","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clinsp.2026.100865_bib0005","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clinsp.2026.100865_bib0006","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clinsp.2026.100865_bib0007","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3324\/haematol.2023.283557","article-title":"Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory follicular lymphoma: a phase Ib\/II study","volume":"109","author":"Flowers","year":"2024","journal-title":"Haematologica"},{"issue":"10232","key":"10.1016\/j.clinsp.2026.100865_bib0008","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinsp.2026.100865_bib0009","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study","volume":"7","author":"Townsend","year":"2023","journal-title":"Hemasphere"},{"issue":"15","key":"10.1016\/j.clinsp.2026.100865_bib0010","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinsp.2026.100865_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinsp.2026.100865_bib0012","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Pan","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinsp.2026.100865_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/jpps.2023.11235","article-title":"Gastrointestinal perforation associated with novel antineoplastic agents: a real-world study based on the FDA adverse event reporting system","volume":"26","author":"Yu","year":"2023","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.clinsp.2026.100865_bib0014","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinsp.2026.100865_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinsp.2026.100865_bib0016","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J Affect Disord"},{"issue":"22","key":"10.1016\/j.clinsp.2026.100865_bib0017","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clinsp.2026.100865_bib0018","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.clinsp.2026.100865_bib0019","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/imr.13265","article-title":"Antibody-mediated phagocytosis in cancer immunotherapy","volume":"319","author":"Van Wagoner","year":"2023","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.clinsp.2026.100865_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","article-title":"Update on the application of monoclonal antibody therapy in primary membranous nephropathy","volume":"83","author":"Deng","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.clinsp.2026.100865_bib0021","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","article-title":"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"127","author":"Byrd","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clinsp.2026.100865_bib0022","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"F\u00fcrstenau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clinsp.2026.100865_bib0023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/j.clinsp.2026.100865_bib0024","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinsp.2026.100865_bib0025","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/DDDT.S212500","article-title":"Clinical application of obinutuzumab for treating chronic lymphocytic leukemia","volume":"13","author":"Luan","year":"2019","journal-title":"Drug Des Devel Ther."},{"issue":"7","key":"10.1016\/j.clinsp.2026.100865_bib0026","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40265-022-01715-1","article-title":"Lupus Nephritis: Improving Treatment Options","volume":"82","author":"Kostopoulou","year":"2022","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.clinsp.2026.100865_bib0027","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.3390\/jcm13113064","article-title":"Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults","volume":"13","author":"Bernardi","year":"2024","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.clinsp.2026.100865_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083277","article-title":"Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas","volume":"14","author":"McGovern","year":"2024","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.clinsp.2026.100865_bib0029","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.clinsp.2026.100865_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ijn.12412","article-title":"Prevention and management of obinutuzumab-associated toxicities: Australian experience","volume":"21","author":"Snowden","year":"2015","journal-title":"Int J Nurs Pract"},{"issue":"9","key":"10.1016\/j.clinsp.2026.100865_bib0031","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3201\/eid2109.150104","article-title":"Disseminated enteroviral infection associated with obinutuzumab","volume":"21","author":"Dendle","year":"2015","journal-title":"Emerg Infect Dis."},{"issue":"2","key":"10.1016\/j.clinsp.2026.100865_bib0032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2169\/internalmedicine.3334-23","article-title":"Primary adrenal insufficiency triggered by cytomegalovirus infection after obinutuzumab plus bendamustine therapy for follicular lymphoma","volume":"64","author":"Nakamura","year":"2025","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.clinsp.2026.100865_bib0033","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/09513590.2010.507281","article-title":"Estrogen promotes B cell activation in vitro through down-regulating CD80 molecule expression","volume":"27","author":"Fu","year":"2011","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.clinsp.2026.100865_bib0034","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/endrev\/bnac017","article-title":"Estrogen receptor signaling in the immune system","volume":"44","author":"Chakraborty","year":"2023","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.clinsp.2026.100865_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29298","article-title":"The role of sex hormones and receptors in HBV infection and development of HBV-related HCC","volume":"95","author":"Nuermaimaiti","year":"2023","journal-title":"J Med Virol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:14:19Z","timestamp":1793963659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593226000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S1807593226000062"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.100865","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.100865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100865"}}